estim
mortal
associ
cardiomyopathi
per
global
popul
correspond
death
increas
per
estim
may
affect
bia
due
misclassif
miss
incomplet
data
among
other
addit
need
intern
consortia
group
cohort
patient
overcom
issu
low
number
event
followup
annual
chang
cardiomyopathi
percentag
death
shown
fig
caus
heart
failur
aris
dcm
occur
pump
failur
due
dilat
wherea
sudden
cardiac
death
arrhythmia
account
remain
surviv
patient
dcm
develop
heart
failur
improv
time
develop
countri
improv
surviv
attribut
larg
part
increas
avail
use
angiotensinconvert
enzym
ace
inhibitor
implant
icd
heart
howev
intervent
avail
world
popul
furthermor
effect
medic
ventricular
devic
heart
transplant
natur
histori
dcm
well
character
despit
advanc
manag
heart
failur
patient
dcm
still
substanti
mortal
risk
develop
congest
heart
failur
higher
black
white
individu
find
explain
confound
variabl
hypertens
socioeconom
sever
studi
report
rel
risk
mortal
dcm
black
compar
agematch
white
black
ethnic
also
associ
poor
outcom
acut
idiopath
euroheart
failur
survey
ii
examin
data
accord
sex
found
dcm
occur
often
men
howev
epidemiolog
studi
report
data
accord
sex
studi
compar
sex
differ
dcm
phenotyp
sever
outcom
populationbas
epidemiolog
studi
idiopath
dcm
minnesota
report
male
femal
ratio
multicentr
imac
intervent
myocard
acut
cardiomyopathi
studi
men
left
ventricular
lv
eject
fraction
lvef
fraction
volum
fluid
eject
left
ventricl
contract
physiolog
valu
month
heart
failur
symptom
durat
myocard
inflamm
myocardium
acut
onset
idiopath
dcm
idiopath
dcm
month
symptom
durat
wors
recoveri
assess
new
york
heart
associ
nyha
classif
reduc
transplantfre
surviv
find
similar
data
patient
heart
failur
multisit
studi
usa
canada
dcm
common
form
cardiomyopathi
among
children
individu
year
age
idiopath
dcm
wherea
dcm
due
known
caus
myocard
neuromuscular
annual
incid
dcm
children
rang
per
annual
incid
higher
boy
girl
black
individu
white
infant
year
age
older
north
america
children
dcm
progress
heart
failur
receiv
heart
transplant
within
year
diagnosi
figur
increas
year
risk
factor
increas
risk
death
heart
transplant
includ
congest
heart
failur
increas
lv
endsystol
dimens
zscore
paramet
often
use
children
surrog
lvef
diagnosi
older
age
curat
strength
evid
suggest
gene
mutat
caus
dcm
fundament
clinic
care
one
adjud
variant
pathogenet
probabl
pathogenet
relev
gene
caus
dcm
uncertain
gene
curat
also
fundament
import
discoveri
dcmassoci
gene
level
evid
requir
chang
classif
gene
gene
uncertain
signific
dcm
gene
confirm
relev
one
routin
includ
clinic
test
panel
unclear
ideal
gene
discoveri
scenario
one
larg
multigener
dcm
pedigre
numer
affect
famili
member
sever
smaller
famili
famili
rare
gene
variant
unaffect
individu
carri
variant
addit
support
evid
would
genomewid
sequenc
exclud
presenc
rare
variant
establish
dcmassoci
gene
howev
scenario
rare
achiev
dcm
usual
lethal
condit
larg
famili
exist
reason
studi
includ
cohort
individu
patient
dcm
whose
dcmassoci
candid
gene
sequenc
rare
code
variant
identifi
number
individu
rare
variant
gene
compar
number
individu
larg
publicli
access
refer
data
set
also
carri
rare
code
variant
largest
public
databas
genom
aggreg
databas
gnomad
expans
exom
aggreg
consortium
exac
databas
exom
genom
sequenc
individu
gener
popul
presum
known
dcm
respons
need
systemat
approach
gene
clingen
larg
collabor
effort
sponsor
us
nation
human
genom
research
publish
systemat
approach
integr
genet
experiment
evid
relationship
approach
use
semiquantit
score
system
valid
across
sever
mendelian
diseas
result
evid
support
associ
specif
gene
diseas
classifi
definit
strong
moder
limit
absent
conflict
approach
use
clingen
cardiovascular
diseas
work
gene
curat
hypertroph
curat
gene
associ
arrhythmogen
right
ventricular
cardiomyopathi
dcm
underway
like
gene
curat
variant
curat
also
challeng
even
wellestablish
dcmassoci
gene
patient
dcm
sequenc
establish
candid
dcmassoci
gene
lead
identif
rare
variat
exampl
allel
frequenc
commonli
rare
variant
howev
presenc
uniqu
rare
variant
necessarili
assign
causal
dcm
variant
furthermor
plethora
rare
variant
identifi
exom
genom
sequenc
challeng
prior
variant
adjud
avail
larg
genet
data
set
divers
ethnic
group
brought
new
challeng
variant
consid
rare
comparison
control
dna
sampl
hundr
individu
common
previous
thought
unlik
diseas
caus
studi
leverag
exac
databas
exom
shown
frequenc
rare
variant
control
popul
mirror
gene
propos
relev
hypertroph
therebi
question
relev
attribut
variant
paradigm
also
applic
dcm
american
colleg
medic
genet
substanti
revis
approach
variant
clinic
sequenc
make
approach
applic
standard
much
rigor
overal
effect
make
interpret
conserv
adjud
variant
pathogenet
probabl
pathogenet
variant
consid
probabl
pathogenet
probabl
variant
pathogenet
variant
meet
rigor
standard
note
variant
uncertain
signific
furthermor
recent
develop
rapidli
expand
databas
assert
variant
patholog
publicli
access
databas
clingen
interact
clinvar
popul
clinvar
curat
variant
medic
relev
gene
includ
associ
cardiomyopathi
final
frontier
dcm
genet
may
deciph
interrelationship
genet
diseas
pathway
establish
nongenet
diseas
mechan
includ
exampl
immunolog
infecti
larg
studi
link
genet
nongenet
caus
unifi
research
approach
yet
accomplish
infect
believ
account
aetiolog
dcm
typic
associ
myocard
demonstr
anim
model
one
common
group
virus
associ
dcm
enterovirus
includ
coxsackieviru
group
b
particular
box
adenovirus
herpesvirus
also
commonli
found
patient
less
well
establish
role
parvovirus
associ
dcm
analysi
myocardi
biopsi
sampl
patient
dcm
identifi
molecular
evid
viral
genom
evid
viral
posit
identif
viral
genom
biopsi
associ
morerapid
progress
dcm
wors
clinic
sever
line
evid
indic
dcm
result
autoimmun
diseas
accord
rosewitebski
criteria
evid
includ
presenc
cardiac
immun
cell
infiltr
biopsi
sampl
abnorm
express
hla
class
ii
andor
adhes
molecul
essenti
initi
immun
respons
mediat
hla
class
ii
therefor
use
biomark
identifi
autoimmun
diseas
cardiac
microvascular
endothelium
absenc
viral
genom
detect
biopsi
sampl
index
patient
famili
increas
serum
level
cardiac
autoantibodi
patient
experiment
induc
anim
model
dcm
immun
recogn
autoantigen
also
found
patient
respons
immunosuppress
immunomodul
patient
suspect
autoimmun
furthermor
autoimmun
diseas
system
lupu
erythematosu
system
sclerosi
rheumatoid
arthriti
rare
caus
dcm
occur
cardiacspecif
autoantibodi
occur
patient
dcm
rel
directli
influenc
myocyt
function
prognosi
patient
inflammatori
dcm
may
associ
hla
antigen
describ
landmark
multicentr
european
genomewid
associ
studi
report
hla
risk
locu
dcm
consist
autoimmun
dcm
probabl
repres
end
result
one
aetiolog
agent
individu
patient
multipl
hit
cascad
involv
best
depict
applic
new
complex
classif
moge
model
fit
perfectli
autoimmun
dcm
phenotyp
mani
distinct
cardiac
autoantibodi
found
patient
cardiac
heavychain
isoform
frequent
recogn
autoantibodi
seem
direct
function
pathogenet
furthermor
immun
anim
autoantigen
identifi
patient
dcm
receptor
muscarin
acetylcholin
receptor
cardiac
myosin
heavi
chain
cardiac
lead
cardiac
abnorm
reproduc
dcm
phenotyp
note
myocardi
patholog
produc
transfer
immun
compon
one
experiment
anim
passiv
transfer
antibodi
purifi
rat
immun
cardiac
myosin
lead
deposit
antibodi
myocardium
myocyt
apoptosi
produc
cardiomyopathi
recipi
mous
model
autoimmun
myocard
dcm
induc
immun
heavi
chain
kinas
also
known
mitogenactiv
protein
kinas
kinas
kinas
mediat
rapid
wnt
protein
secret
result
myofibroblast
differenti
myocardi
fibrosi
progress
suggest
possibl
mechan
autoimmun
promot
remodel
lead
myosin
heavi
chain
relev
autoantigen
patient
autoimmun
pharmacolog
target
wnt
protein
might
repres
promis
therapeut
approach
chronic
alcohol
abus
import
caus
dcm
occur
often
men
year
age
heavi
consum
alcohol
least
proport
alcohol
cardiomyopathi
among
cardiomyopathi
death
estim
alcohol
dcm
occur
often
men
women
studi
anim
demonstr
acut
chronic
ethanol
administr
impair
cardiac
decreas
contractil
protein
heavi
metabolit
alcohol
acetaldehyd
alter
cellular
calcium
magnesium
phosphat
homeostasi
impair
mitochondri
respir
damag
myocardium
alcohol
also
recruit
inflammatori
cell
longterm
abus
cocain
also
known
caus
dcm
lethal
depress
lv
function
report
individu
use
cocain
cardiac
cocain
believ
caus
lv
dysfunct
increas
releas
catecholamin
directli
toxic
cardiomyocyt
lead
necrosi
similar
effect
alcohol
cocain
also
caus
myocyt
death
damag
myocard
report
patient
die
suspect
cocain
overdos
suggest
myocardi
inflamm
may
lead
dcm
least
dcm
occur
advers
effect
cancer
chemotherapeut
agent
anthracyclin
frequent
caus
dcm
includ
doxorubicin
epirubicin
idarubicin
doxorubicin
wide
use
effect
chemotherapi
treatment
mani
adult
paediatr
cancer
howev
one
advers
effect
cumul
doserel
progress
myocardi
damag
may
lead
dcm
congest
heart
doxorubicin
bind
dna
type
ii
topoisomeras
lead
dna
doublestrand
break
transcriptom
chang
result
mitochondri
dysfunct
reactiv
oxygen
speci
gener
cardiac
cell
children
cancer
receiv
anthracyclin
result
surviv
develop
least
form
cardiac
dysfunct
lead
cardiomyocyt
necrosi
apoptosi
hypertrophi
fibrosi
lv
dysfunct
dcm
heart
endomyocardi
biopsi
emb
sampl
reveal
featur
cardiotox
cytosol
vacuol
lysi
myofibril
cellular
swell
troponin
marker
myocardi
injuri
use
serum
biomark
doxorubicin
cardiotox
predict
progress
sex
hormon
alter
cardiac
function
bind
androgen
oestrogen
receptor
cardiac
vascular
endotheli
cell
smooth
muscl
cell
fibroblast
myocyt
addit
bind
sex
hormon
receptor
directli
alter
function
immun
cell
platelet
influenc
type
cardiac
inflamm
remodel
thrombosi
involv
mani
inflammatori
cell
cytokin
drive
dilat
occur
often
men
also
predispos
patient
dcm
thromboembol
event
includ
complement
platelet
importantli
women
higher
level
oestrogen
receptor
arteri
men
activ
receptor
prevent
cardiomyocyt
apoptosi
inhibit
cardiac
damag
induc
reactiv
oxygen
speci
reduc
cardiac
hypertrophi
fibrosi
anim
model
androgen
promot
overal
underli
sex
differ
cardiac
pathophysiolog
immun
respons
cardiac
injuri
believ
lead
observ
sex
differ
dcm
heart
failur
doppler
echocardiographi
remain
primari
method
analys
cardiac
function
undergird
diagnost
criteria
heart
muscl
diseas
thu
patient
unexplain
suspect
moder
sever
heart
failur
symptom
undergo
echocardiographi
first
present
echocardiogram
featur
indic
specif
aetiolog
howev
echocardiographi
definit
establish
underli
caus
dcm
exampl
wall
motion
abnorm
nonischaem
origin
suggest
myocard
addit
lv
remodel
function
mitral
regurgit
assess
effici
echocardiographi
lv
dilat
concomit
displac
papillari
muscl
caus
tether
mitral
leaflet
poor
valv
coaptat
closur
speckletrack
echocardiographi
imag
techniqu
analys
motion
tissu
heart
use
natur
occur
speckl
pattern
myocardium
promis
tool
identifi
presenc
inflammatori
infiltr
patient
dcm
fig
patient
biopsyproven
myocard
global
longitudin
strain
longitudin
shorten
percentag
provid
accur
assess
region
contractil
significantli
impair
compar
patient
without
cardiac
mri
becom
increasingli
access
clinic
practic
repres
best
method
morpholog
function
evalu
character
myocardi
tissu
patient
dcm
fig
presenc
myocardi
fibrosi
detect
late
gadolinium
enhanc
lge
lge
distribut
may
indic
muscular
dystrophi
lge
presenc
pattern
quantif
may
assist
determin
risk
malign
ventricular
arrhythmia
mri
detect
myocardi
oedema
suggest
acut
myocard
sarcoidosi
inflammatori
diseas
granuloma
form
differ
organ
alongsid
cardiac
mri
fdg
emerg
valuabl
tool
diagnos
cardiac
sarcoidosi
howev
sensit
cardiac
mri
detect
inflamm
dcm
low
inflamm
scarc
stage
diseas
process
best
method
confirm
presenc
inflammatori
infiltr
dcm
histolog
andor
addit
cardiac
mri
detect
presenc
viru
futur
multicentr
prospect
studi
need
confirm
role
cardiac
mri
prognost
stratif
dcm
current
expert
consensu
statement
esc
recommend
patient
suspect
inflammatori
cardiomyopathi
undergo
emb
identifi
type
inflammatori
infiltr
determin
underli
aetiolog
form
aetiologybas
treatment
although
mani
centr
conduct
emb
basi
percept
procedur
carri
high
risk
complic
sever
studi
report
emb
perform
low
rate
major
complic
lv
biopsi
safe
right
ventricular
tissu
obtain
emb
analys
use
histolog
immunohistochemistri
molecular
biolog
techniqu
histolog
examin
paraffin
section
variou
stain
protocol
use
detect
sever
morpholog
alter
myocardi
disarray
loss
parallel
align
cardiomyocyt
vacuol
format
cardiomyocyt
hypertrophi
myocytolysi
myofibrillar
degener
subleth
injuri
cardiac
muscl
cell
necrosi
cell
death
scar
format
collagen
deposit
fibrosi
patholog
vascular
condit
granuloma
giant
cell
multinucl
cell
form
fusion
cell
character
major
inflammatori
subtyp
fig
use
immunohistochemistri
markedli
increas
abil
detect
cardiac
inflamm
biopsi
section
monoclon
antibodi
enabl
precis
character
quantif
local
differ
immun
cell
type
celladhes
molecul
determin
cell
composit
inflammatori
foci
affect
prognosi
dcm
establish
proport
type
immun
cell
crucial
decid
optim
type
treatment
microbi
genom
determin
quantifi
sequenc
use
pcrbase
method
includ
nest
revers
quantit
pcr
activ
latent
infect
myocardium
differenti
parallel
blood
test
confirm
transcript
activ
emb
sampl
princip
virus
respons
inflammatori
cardiomyopathi
viral
titr
serum
alon
use
diagnosi
correl
actual
phase
cardiomyopathi
final
novel
biomark
microrna
gene
express
profil
introduc
molecular
examin
emb
identif
distinct
gene
express
profil
myocardium
enabl
clear
discrimin
sampl
giant
cell
acut
myocard
inflamm
even
direct
histolog
proof
giant
cell
inflamm
moreov
diseasespecif
gene
express
profil
chang
effect
treatment
therebi
also
use
monitor
sudden
cardiac
death
dcm
caus
electromechan
dissoci
pulseless
electr
activ
ventricular
arrhythmia
develop
new
lv
branch
block
followup
strong
independ
prognost
predictor
allcaus
mortal
atrial
fibril
sign
structur
diseas
progress
neg
affect
prognosi
patient
dcm
haemodynam
relev
mitral
regurgit
may
need
invas
therapi
percutan
open
repair
mitral
valv
mechan
circulatori
support
even
heart
transplant
wherea
right
ventricular
function
frequent
recov
therapi
typic
within
month
develop
right
ventricular
dysfunct
longterm
followup
indic
structur
diseas
progress
portend
neg
outcom
strategi
detect
presymptomat
dcm
clear
rational
earli
treatment
retard
advers
remodel
prevent
heart
failur
symptom
increas
life
expect
addit
patient
dcm
regularli
reassess
particularli
presenc
cardiovascular
risk
factor
worsen
lv
function
increas
ventricular
arrhythm
burden
caus
dcm
progress
also
develop
new
copatholog
thu
possibl
presenc
coronari
arteri
diseas
hypertens
heart
diseas
structur
valv
diseas
acut
myocard
systemat
rule
followup
howev
clinic
echocardiograph
paramet
limit
abil
predict
longterm
prognosi
suggest
factor
import
determin
outcom
dcm
persist
enteroviru
myocardium
associ
ventricular
dysfunct
wherea
viral
genom
clearanc
associ
improv
ventricular
function
differ
virus
respond
differ
antivir
drug
sometim
complet
elimin
know
specif
pathogen
viru
crucial
make
tailor
treatment
decis
clinic
experiment
studi
immunohistolog
evid
inflamm
identifi
independ
predictor
thu
precis
character
quantif
intramyocardi
immun
cell
subtyp
need
inform
decis
start
immunosuppress
therapi
goal
improv
evid
suggest
exercis
benefici
heart
failur
although
elderli
patient
enrol
studi
optimum
level
intens
exercis
prescrib
furthermor
larg
trial
exercis
patient
heart
failur
hfaction
show
modest
treatment
effect
obtain
intens
train
regimen
may
practic
deliv
everi
healthcar
centr
importantli
exercis
contraind
activ
phase
inflammatori
cardiomyopathi
athlet
nonathlet
dcm
due
lamin
ac
ace
inhibitor
angiotensin
receptor
antagonist
patient
develop
cough
advers
effect
ace
inhibitor
standard
drug
therapi
heart
failur
dcm
tabl
combin
angiotensin
inhibitor
reduc
total
mortal
hospit
admiss
compar
ace
inhibitor
could
replac
ace
inhibitor
one
cornerston
drug
therapi
chronic
heart
mineralocorticoid
antagonist
inhibitor
provid
increment
benefit
surviv
hospit
admiss
combin
ace
inhibitor
pharmacolog
therapi
use
accord
intern
guidelin
take
account
blood
pressur
heart
rate
rhythm
renal
function
blood
chemistri
cardiac
resynchron
therapi
crt
modal
cardiac
pace
use
patient
lv
systol
dysfunct
dyssynchron
ventricular
activ
provid
simultan
nearli
simultan
electr
activ
left
ventricl
right
ventricl
via
stimul
biventricular
pace
left
ventricl
alon
therapi
perform
either
crtpacemak
crtp
combin
addit
pacemak
function
deliv
electr
shock
reset
sinu
rhythm
case
arrhythmia
crt
devic
includ
transven
pace
lead
place
branch
coronari
sinu
less
commonli
epicardi
endocardi
lv
lead
lv
pace
addit
lead
right
ventricl
right
atrium
crt
indic
patient
heart
failur
lvef
life
expect
good
function
statu
year
sinu
rhythm
markedli
prolong
qr
durat
ms
ecg
show
left
bundl
branch
block
irrespect
symptom
sever
benefit
crt
patient
right
bundl
branch
block
interventricular
conduct
delay
unclear
subgroup
analys
suggest
littl
benefit
even
harm
two
random
placebocontrol
trial
comparison
medic
therapi
pace
defibril
heart
failur
companion
cardiac
resynchron
heart
failur
carehf
studi
random
patient
moder
sever
symptomat
heart
failur
nyha
class
iii
iv
either
optim
medic
therapi
optim
medic
therapi
plu
trial
crt
reduc
risk
death
caus
hospit
admiss
worsen
heart
failur
rel
risk
ratio
death
crtp
crticd
crtd
companion
studi
crtp
carehf
studi
carehf
studi
rel
risk
ratio
hospit
crtp
trial
also
show
crt
improv
symptom
qualiti
life
qol
ventricular
function
similarli
two
random
placebocontrol
trial
evalu
effect
crt
patient
mild
symptom
nyha
class
heart
failur
maditcrt
trial
moder
symptom
nyha
class
ii
heart
failur
resynchronizationdefibril
ambulatori
heart
failur
trial
raft
patient
receiv
either
optim
medic
therapi
plu
icd
maintain
spontan
sinu
rhythm
optim
medic
therapi
plu
crtd
pace
control
icd
trial
crt
reduc
risk
primari
composit
end
point
death
heart
failur
hospit
rel
risk
ratio
maditcrt
rel
risk
ratio
raft
allcaus
mortal
significantli
reduc
raft
maditcrt
crt
improv
symptom
qol
ventricular
function
patient
popul
well
maditcrt
raft
show
signific
treatmentbysubgroup
interact
wherebi
qr
durat
modifi
treatment
effect
crt
seem
effect
patient
qr
ms
crt
benefici
patient
left
bundl
branch
block
right
bundl
branch
block
interventricular
conduct
defect
metaanalysi
mortal
benefit
crt
similar
individu
ischaem
diseas
nonischaem
thu
trial
crt
reduc
risk
death
improv
symptom
qol
ventricular
function
definit
diagnosi
pathophysiolog
underli
dcm
prerequisit
specif
person
therapi
base
howev
treatment
guidelin
caus
inflammatori
dcm
miss
time
thu
multicentr
prospect
random
studi
test
immunosuppress
antivir
therapi
inflammatori
dcm
need
retrospect
analysi
show
immunosuppress
treatment
patient
embproven
virusposit
cardiomyopathi
consequ
prospect
random
placebocontrol
studi
timictri
show
patient
embproven
chronic
virusneg
myocard
refractori
standard
therapi
immunosuppress
therapi
result
signific
improv
lvef
compar
indic
immunosuppress
therapi
effect
patient
inflammatori
dcm
result
subsequ
confirm
anoth
ideal
immunosuppress
therapi
start
earli
possibl
irrevers
remodel
viral
infect
frequent
caus
myocard
lead
inflammatori
dcm
biopsybas
analysi
patient
myocard
presenc
viru
myocardium
associ
progress
impair
lv
function
wherea
spontan
viral
clearanc
associ
signific
improv
lv
consequ
nonrandom
studi
patient
enterovirusassoci
adenovirusassoci
cardiomyopathi
administr
significantli
reduc
viru
load
reduc
myocardi
injuri
improv
longterm
betainterferon
chronic
viral
cardiomyopathi
bicc
trial
viru
load
reduct
clearanc
significantli
higher
group
placebo
group
howev
treatment
statist
significantli
less
effect
clear
parvoviru
final
small
openlabel
studi
found
remov
circul
autoantibodi
immunoadsorpt
improv
cardiac
function
decreas
myocardi
howev
present
immunoadsorpt
still
experiment
treatment
option
conflict
result
regard
effect
placebocontrol
multicentr
studi
underway
test
therapi
patient
tabl
current
risk
stratif
scheme
predict
lifethreaten
arrhythmia
patient
dcm
base
mainli
degre
systol
dysfunct
left
ventricl
lvef
set
threshold
high
risk
sudden
death
basi
result
random
clinic
although
data
support
use
icd
robust
patient
ischaem
dcm
evid
random
trial
patient
nonischaem
dcm
debat
time
current
european
american
colleg
cardiologyamerican
heart
associ
guidelin
icd
implant
patient
nonischaem
dcm
base
metaanalysi
includ
trial
icd
implant
primari
prevent
sudden
cardiac
death
trial
icd
implant
secondari
prevent
measur
patient
surviv
episod
ventricular
fibril
demonstr
reduct
allcaus
mortal
icd
danish
trial
defibril
implant
patient
nonischem
systol
heart
failur
patient
nonischaem
dcm
optim
medic
therapi
crt
randomli
assign
icd
versu
icd
primari
prevent
sudden
cardiac
death
differ
allcaus
mortal
primari
end
point
observ
two
group
result
danish
studi
might
explain
overal
low
mortal
control
group
possibl
justifi
high
use
crt
high
adher
optim
medic
therapi
group
may
reduc
power
studi
prove
efficaci
icd
nevertheless
remark
icd
group
show
reduct
incid
sudden
cardiac
death
also
overal
surviv
benefit
subgroup
patient
year
age
updat
metaanalysi
six
random
trial
assess
effect
icd
allcaus
mortal
patient
nonischaem
dcm
random
icd
optim
medic
therapi
primari
prevent
sudden
cardiac
death
found
signific
risk
reduct
allcaus
mortal
icd
interestingli
result
remain
relev
statist
signific
elimin
contribut
trial
involv
patient
crtd
reduct
allcaus
mortal
icd
problem
use
lvef
pivot
risk
marker
patient
dcm
singl
paramet
recapitul
complex
diseas
aris
number
differ
aetiolog
avail
studi
patient
dcm
enabl
physician
identifi
popul
increas
risk
sudden
cardiac
death
patient
mutat
lmna
fnlc
increas
avail
person
aetiolog
diagnosi
patient
dcm
possibl
provid
morerefin
risk
stratif
scheme
addit
lvef
take
account
genet
inform
addit
clinic
paramet
possibl
combin
multiparametr
score
promis
approach
risk
stratif
includ
assess
lge
cardiac
mri
cardiac
sympathet
nerv
function
metaiodobenzylguanidin
label
mibg
healthrel
qol
patient
dcm
poorli
analys
mani
patient
dcm
progress
chronic
heart
failur
patient
awar
risk
die
advers
effect
therapi
frequent
hospit
consider
neg
effect
patient
recent
identifi
three
factor
predict
posit
selfcar
complianc
treatment
clear
inform
medic
belief
ill
seriou
consequ
effect
medic
use
lifestyl
moreov
previou
studi
show
signific
improv
aspect
qol
comprehens
cardiac
rehabilit
daili
light
exercis
weight
manag
programm
nursel
patient
thu
import
way
improv
qol
patient
dcm
provid
earli
pathophysiologicalbas
diagnosi
better
risk
stratif
ultim
person
therapi
base
aetiolog
assess
diseas
refin
current
diagnost
tool
imag
modal
could
revolution
understand
pathogenesi
diseas
import
tool
better
understand
relationship
cardiac
inflamm
develop
use
preclin
mous
model
myocard
advanc
detect
cardiac
new
imag
marker
anim
studi
success
detect
inflamm
patient
myocard
could
refin
detect
inflamm
patient
dcm
inflammatori
cell
often
scarc
echocardiographi
establish
method
assess
systol
dysfunct
advanc
echocardiographi
techniqu
measur
global
longitudin
strain
tissu
doppler
strain
speckletrack
echocardiographi
potenti
enabl
much
earlier
detect
systol
dysfunct
lead
dcm
especi
echocardiographi
result
pair
serum
biomark
heart
failur
bnp
prontbnp
solubl
receptorlik
also
known
creactiv
protein
crp
advanc
genet
sequenc
molecular
analysi
gene
protein
involv
pathogenesi
dcm
preclin
anim
model
human
studi
unveil
promis
new
serum
biomark
use
indic
risk
heart
failur
prognosi
also
reveal
underli
patholog
therebi
inform
treatment
elev
serum
level
correl
sever
heart
failur
nyha
class
patient
myocard
dcm
well
cardiovascular
cytokin
induc
biomechan
strain
cardiac
fibroblast
cardiomyocyt
vascular
endotheli
small
studi
significantli
higher
patient
dcm
found
predict
risk
develop
heart
failur
patient
dcm
sever
recent
combin
ntprobnp
releas
condit
pressur
overload
therefor
marker
heart
failur
serum
level
provid
addit
valu
predict
sudden
death
patient
heart
failur
lvef
two
import
process
heart
failur
inflamm
renal
impair
increas
serum
immunoglobulin
free
light
chain
flc
concentr
sum
circul
flc
increas
patient
autoimmun
dcm
amat
unpublish
result
communitybas
studi
individu
gener
popul
show
high
flc
concentr
associ
increas
risk
allcaus
flc
especi
increas
patient
myocard
associ
mortal
amat
unpublish
result
combin
flc
sum
flc
shown
associ
high
combin
flc
provid
increment
prognost
valu
multipl
patient
recent
hospit
decompens
heart
failur
mechan
flc
increas
dcm
heart
failur
remain
clarifi
flc
may
promis
new
biomark
inflamm
dcm
futur
studi
also
aim
better
understand
relationship
viral
parasit
infect
trypanosoma
cruzi
infect
develop
dcm
infect
remain
endem
mani
countri
probabl
contribut
emerg
public
health
burden
dcm
particular
import
determin
relationship
infect
host
immun
respons
context
host
genet
addit
hepat
hepat
c
viru
hcv
infect
frequent
caus
cardiac
renal
abnorm
includ
hypertroph
cardiomyopathi
dcm
egypt
patient
hcv
infect
echocardiograph
abnorm
frequent
found
dilat
left
atrium
dilat
hypertrophi
left
ventricl
disturb
diastol
systol
function
left
china
ntprobnp
level
higher
patient
hcvinfectionassoci
hepat
hepat
b
viru
infect
healthi
associ
major
histocompat
complex
mhc
antigen
hcv
clearanc
suscept
molecular
mechan
behind
develop
cardiomyopathi
hcv
infect
relat
mhc
class
ii
molecul
found
differ
dcm
hypertroph
antivir
treatment
hcv
infect
report
improv
renal
cardiovascular
outcom
patient
diabet
annual
number
death
associ
hcv
higher
nation
notifi
infecti
condit
suggest
viral
infect
could
make
import
contribut
dcm
case
develop
countri
mechan
hcv
caus
dcm
remain
elucid
preclin
clinic
evid
support
form
dcm
result
pathogenet
autoimmun
mice
lack
cell
receptor
costimulatori
receptor
program
cell
death
protein
spontan
develop
autoimmun
dcm
autoantibodi
bind
cardiac
troponin
passiv
transfer
monoclon
antibodi
direct
cardiac
troponin
induc
cardiac
antibodi
cardiac
troponin
found
patient
myocard
presenc
biomark
probabl
reflect
damag
cardiac
futur
experiment
clinic
studi
need
clarifi
role
autoimmun
autoantibodi
pathogenesi
dcm
serum
autoantibodi
may
form
inexpens
earli
screen
method
determin
subset
patient
increas
risk
develop
dcm
clinic
anim
studi
also
need
find
novel
therapi
improv
efficaci
safeti
case
embproven
virusneg
autoimmun
dcm
without
serum
cardiacspecif
autoantibodi
rapidli
emerg
promis
new
area
medicin
potenti
regener
damag
scar
heart
tissu
patient
dcm
care
improv
cardiovascular
medicin
improv
reperfus
therapi
implant
defibril
novel
medic
cardiac
transplant
mortal
decreas
advanc
area
particularli
import
dcm
diseas
often
detect
end
stage
scar
tissu
well
establish
refractori
medic
revers
process
promis
new
tool
includ
mesenchym
stem
cell
purifi
platelet
exosom
product
fatderiv
extracellular
vesicl
other
extracellular
vesicl
morepurifi
form
term
exosom
deriv
cell
adipocyt
platelet
healthi
individu
import
celltocel
commun
found
contain
mani
regulatori
factor
protein
rna
lipid
inhibit
proinflammatori
profibrot
although
mani
therapi
yet
appli
patient
dcm
clinic
set
hold
promis
therapi
could
prevent
revers
remodel
promot
cardiac
